Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Shock

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|July 30, 2020
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptorsAnthony Shock, David Humphreys, Falk Nimmerjahn
International Reviews of Immunology|October 23, 2012
CD22 and autoimmune diseaseThomas Dörner, Anthony Shock, Kenneth G C Smith
European Journal of Immunology|June 30, 2016
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22Lamia Özgör, Carolin Brandl, Anthony Shock, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2021
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinicRocio Lledo-Garcia, Kate Dixon, Anthony Shock, et al.
Autoimmunity Reviews|July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosusThomas Dörner, Anthony Shock, David M Goldenberg, et al.
Arthritis Research & Therapy|May 17, 2017
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingNatalia V Giltiay, Geraldine L Shu, Anthony Shock, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 28, 2021
Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex CongenitaEster Coutinho, Leslie Jacobson, Anthony Shock, et al.
Arthritis Research & Therapy|July 18, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patientsVanessa Fleischer, Julia Sieber, Sarah J Fleischer, et al.
Journal of Cell Communication and Signaling|April 30, 2016
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptorSimon Lumb, Sarah J Fleischer, Annika Wiedemann, et al.
British Journal of Pharmacology|January 25, 2020
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in miceAnika Kasprick, Maxi Hofrichter, Bryan Smith, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|July 30, 2020
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptorsAnthony Shock, David Humphreys, Falk Nimmerjahn
International Reviews of Immunology|October 23, 2012
CD22 and autoimmune diseaseThomas Dörner, Anthony Shock, Kenneth G C Smith
European Journal of Immunology|June 30, 2016
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22Lamia Özgör, Carolin Brandl, Anthony Shock, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2021
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinicRocio Lledo-Garcia, Kate Dixon, Anthony Shock, et al.
Autoimmunity Reviews|July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosusThomas Dörner, Anthony Shock, David M Goldenberg, et al.
Arthritis Research & Therapy|May 17, 2017
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingNatalia V Giltiay, Geraldine L Shu, Anthony Shock, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 28, 2021
Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex CongenitaEster Coutinho, Leslie Jacobson, Anthony Shock, et al.
Arthritis Research & Therapy|July 18, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patientsVanessa Fleischer, Julia Sieber, Sarah J Fleischer, et al.
Journal of Cell Communication and Signaling|April 30, 2016
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptorSimon Lumb, Sarah J Fleischer, Annika Wiedemann, et al.
British Journal of Pharmacology|January 25, 2020
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in miceAnika Kasprick, Maxi Hofrichter, Bryan Smith, et al.
Pageof 3